Af­ter sweep of deals in 2023, Gilead to fo­cus on 'late re­search, ear­ly de­vel­op­men­t' pipeline

Gilead is still hunt­ing for deals, par­tic­u­lar­ly in vi­rol­o­gy, on­col­o­gy and in­flam­ma­tion.

Dur­ing Tues­day’s fourth-quar­ter earn­ings call, CEO Daniel O’Day said M&A de­ci­sions will be “dri­ven by the sci­ence,” with a fo­cus on build­ing up the com­pa­ny’s “late re­search, ear­ly de­vel­op­ment pipeline.” He added that the com­pa­ny will con­sid­er lat­er-stage deals “as they fit in­to our port­fo­lio and our range.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER